A Phase 3 interventional study of Olanzapine in Bipolar I Disorder, sponsored by Eli Lilly and Company. Completed at 10 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-07-27.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the efficacy and safety of olanzapine in the long-term treatment for patients with bipolar I disorder, depressed.
This is an open-label, multi-center, long-term treatment study conducted only in Japanese sites. The subjects are patients who fulfill the diagnostic criteria for bipolar I disorder, most recent episode depressed, as defined in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) (296.50=unspecified, 296.52=moderate severity, 296.53=severe without psychotic features, 296.54=severe with psychotic features), who have completed Study HGMP (NCT#00510146) and patients who did not participate in Study HGMP who have been recruited to participate in Study HGMS.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received olanzapine 5-20 mg/day in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
Drug: Olanzapine
Participants who received placebo in acute phase of Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
Drug: Olanzapine
Participants who did not participate in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 48 weeks.
Drug: Olanzapine
5-20 mg/day, oral, daily
Also known as: LY170053
Percentage of Participants With Adverse Events Leading to Discontinuation
An adverse event (AE) is an untoward medical event associated with the use of the study drug or study procedure, whether or not it is considered related to the study drug or study procedure. Results presented are the percentage of participants who experienced an adverse event that resulted in the discontinuation of the study.
Time frame: Baseline through 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Change From Baseline in Glucose and Lipid Panel at Week 24 or Week 48 Endpoint
Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Change From Baseline in Weight at Week 24 or Week 48 Endpoint
Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 24 or Week 48 Endpoint
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 24 or Week 48 Endpoint
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Change From Baseline in Clinical Global Improvement- Bipolar (CGI-BP) at Week 24 or Week 48 Endpoint
CGI-BP is a measure of illness severity especially adapted for bipolar illness. It allows rating of mania, depression, and overall illness. The scores for mania, depression, and overall illness each range from 1 (normal, not ill) to 7 (very seriously ill).
Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Percentage of Participants With Emergence of Mania at Week 24 or Week 48
Emergence of mania is defined as first occurrence of score of \>=15 in the YMRS total score in the post-baseline period of Acute Phase. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
Time frame: 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Percentage of Participants With High Suicidality at Week 24 or Week 48
The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors. Based upon scores, suicidality is defined as Low (1-8), Medium (9-16), and High (\>=17).
Time frame: 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Percentage of Participants With Extra-Pyramidal Symptoms (EPS) at Week 24 or Week 48
EPS symptoms measured by DIEPSS are grouped into 4 categories: Parkinsonism, akathisia, dystonia, and dyskinesia. Severity ranges from level 0 (none, normal) to 4 (severe). A participant is deemed to have EPS at endpoint if they have an abnormal endpoint. Normal baseline Parkinsonism is defined as a score not ≥3 on 1 item or ≥2 on 2 items; abnormal endpoint is a score ≥3 on 1 item or ≥2 on 2 items, or an increase of 3 on Parkinsonism total. Normal baseline akathisia, dystonia and dyskinesia is defined as a score \<2; abnormal endpoint is a score ≥2 or an increase ≥2 from that baseline score.
Time frame: 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Change From Baseline in Hemoglobin (HbA1c) at Week 24 or Week 48 Endpoint
HbA1c is a test that measures the amount of glycated hemoglobin in the blood over prolonged periods of time.
Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Change From Baseline in Prolactin at Week 24 or Week 48 Endpoint
Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Change From Baseline to in QTcF at Week 24 or Week 48 Endpoint
Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval)
Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
| Milestone | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Started | 56 | 25 | 20 |
| Completed | 45 | 20 | 6 |
| Not completed | 11 | 5 | 14 |
| Withdrew: Adverse event | 4 | 3 | 8 |
| Withdrew: Physician decision | 3 | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 1 | 5 |
An adverse event (AE) is an untoward medical event associated with the use of the study drug or study procedure, whether or not it is considered related to the study drug or study procedure. Results presented are the percentage of participants who experienced an adverse event that resulted in the discontinuation of the study.
| percentage of participants | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Percentage of Participants With Adverse Events Leading to Discontinuation | 7.1 | 12.0 | 40.0 |
| millimole/Liter | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Glucose, Fasting | 0.03 ± 0.47 | 0.37 ± 0.55 | 0.68 ± 1.31 |
| Cholesterol | 0.033 ± 0.699 | 0.040 ± 0.716 | 0.086 ± 1.031 |
| Low-density lipoprotein ( LDL) Cholesterol | 0.141 ± 0.676 | -0.034 ± 0.731 | 0.008 ± 0.855 |
| High-density lipoprotein ( HDL) Cholesterol | -0.036 ± 0.221 | -0.046 ± 0.212 | -0.074 ± 0.239 |
| Triglycerides | -0.108 ± 0.543 | 0.485 ± 1.415 | 0.382 ± 1.270 |
| kilograms | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Change From Baseline in Weight at Week 24 or Week 48 Endpoint | 0.29 ± 2.79 | 0.92 ± 3.02 | 5.36 ± 4.34 |
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
| units on a scale | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 24 or Week 48 Endpoint | -0.2 ± 8.3 | -0.4 ± 6.5 | -5.8 ± 11.6 |
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
| units on a scale | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 24 or Week 48 Endpoint | 0.4 ± 1.5 | -0.2 ± 1.0 | -0.1 ± 1.7 |
CGI-BP is a measure of illness severity especially adapted for bipolar illness. It allows rating of mania, depression, and overall illness. The scores for mania, depression, and overall illness each range from 1 (normal, not ill) to 7 (very seriously ill).
| units on a scale | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| CGI-BP Mania | -0.1 ± 0.4 | 0.1 ± 0.3 | 0.1 ± 0.2 |
| CGI-BP Depression | -0.3 ± 0.9 | -0.0 ± 0.9 | -1.1 ± 1.3 |
| CGI-BP Overall Bipolar Illness | -0.3 ± 1.0 | -0.1 ± 0.7 | -0.9 ± 1.1 |
Emergence of mania is defined as first occurrence of score of \>=15 in the YMRS total score in the post-baseline period of Acute Phase. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
| percentage of participants | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Percentage of Participants With Emergence of Mania at Week 24 or Week 48 | 0 | 0 | 0 |
The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors. Based upon scores, suicidality is defined as Low (1-8), Medium (9-16), and High (\>=17).
| percentage of participants | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Percentage of Participants With High Suicidality at Week 24 or Week 48 | 3.6 | 0 | 0 |
EPS symptoms measured by DIEPSS are grouped into 4 categories: Parkinsonism, akathisia, dystonia, and dyskinesia. Severity ranges from level 0 (none, normal) to 4 (severe). A participant is deemed to have EPS at endpoint if they have an abnormal endpoint. Normal baseline Parkinsonism is defined as a score not ≥3 on 1 item or ≥2 on 2 items; abnormal endpoint is a score ≥3 on 1 item or ≥2 on 2 items, or an increase of 3 on Parkinsonism total. Normal baseline akathisia, dystonia and dyskinesia is defined as a score \<2; abnormal endpoint is a score ≥2 or an increase ≥2 from that baseline score.
| percentage of participants | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Akathisia | 0 | 0 | 0 |
| Dyskinesia | 0 | 0 | 0 |
| Dystonia | 0 | 0 | 0 |
| Parkinsonism | 3.6 | 0 | 5.0 |
HbA1c is a test that measures the amount of glycated hemoglobin in the blood over prolonged periods of time.
| percentage of glycated hemoglobin | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Change From Baseline in Hemoglobin (HbA1c) at Week 24 or Week 48 Endpoint | -0.016 ± 0.259 | 0.036 ± 0.243 | 0.180 ± 0.282 |
| microgram/Liter | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Change From Baseline in Prolactin at Week 24 or Week 48 Endpoint | -1.669 ± 10.498 | -0.388 ± 14.179 | 3.383 ± 18.731 |
Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval)
| millisecond (msec) | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Change From Baseline to in QTcF at Week 24 or Week 48 Endpoint | -1.7 ± 16.6 | -8.5 ± 13.1 | -3.4 ± 13.9 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pre-Olanzapine | — | 1/56 (1.8%) | 34/56 (60.7%) |
| Pre-Placebo | — | 0/25 (0%) | 13/25 (52%) |
| New Olanzapine | — | 1/20 (5%) | 20/20 (100%) |
| Event | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Pancreatitis acuteGastrointestinal disorders | 0/56 | 0/25 | 1/20 |
| Cholecystitis acuteHepatobiliary disorders | 0/56 | 0/25 | 1/20 |
| Depressive symptomPsychiatric disorders | 1/56 | 0/25 | 0/20 |
| Event | Pre-Olanzapine | Pre-Placebo | New Olanzapine |
|---|---|---|---|
| Weight increasedInvestigations | 3/56 | 1/25 | 14/20 |
| Increased appetiteMetabolism and nutrition disorders | 0/56 | 0/25 | 9/20 |
| SomnolenceNervous system disorders | 2/56 | 0/25 | 5/20 |
| Alanine aminotransferase increasedInvestigations | 1/56 | 0/25 | 4/20 |
| Blood creatine phosphokinase increasedInvestigations | 0/56 | 1/25 | 4/20 |
| NasopharyngitisInfections and infestations | 7/56 | 1/25 | 3/20 |
| Decreased appetiteMetabolism and nutrition disorders | 1/56 | 0/25 | 3/20 |
| HeadacheNervous system disorders | 4/56 | 3/25 | 2/20 |
| IrritabilityGeneral disorders | 0/56 | 0/25 | 2/20 |
| Aspartate aminotransferase increasedInvestigations | 1/56 | 0/25 | 2/20 |
| Age Continuous(years) | Pre-Olanzapine | Pre-Placebo | New Olanzapine | Total |
|---|---|---|---|---|
| Mean | 39.31 ± 10.48 | 37.53 ± 7.64 | 39.13 ± 9.56 | 38.84 ± 9.61 |
| Sex: Female, Male(Participants) | Pre-Olanzapine | Pre-Placebo | New Olanzapine | Total |
|---|---|---|---|---|
| Female | 34 | 14 | 13 | 61 |
| Male | 22 | 11 | 7 | 40 |
| Race/Ethnicity, Customized(participants) | Pre-Olanzapine | Pre-Placebo | New Olanzapine | Total |
|---|---|---|---|---|
| East Asian | 56 | 25 | 20 | 101 |
| Region of Enrollment(participants) | Pre-Olanzapine | Pre-Placebo | New Olanzapine | Total |
|---|---|---|---|---|
| Japan | 56 | 25 | 20 | 101 |
| Montgomery- Asberg Depression Rating Scale (MADRS) Total Score(units on a scale) | Pre-Olanzapine | Pre-Placebo | New Olanzapine | Total |
|---|---|---|---|---|
| Mean | 8.05 ± 7.50 | 9.72 ± 6.48 | 16.45 ± 9.03 | 10.13 ± 8.18 |
| Young Mania Rating Scale (YMRS) Total Score(units on a scale) | Pre-Olanzapine | Pre-Placebo | New Olanzapine | Total |
|---|---|---|---|---|
| Mean | 0.38 ± 1.10 | 0.40 ± 0.76 | 0.45 ± 0.83 | 0.40 ± 0.97 |
| Clinical Global Improvement- Bipolar (CGI-BP) - Mania(units on a scale) | Pre-Olanzapine | Pre-Placebo | New Olanzapine | Total |
|---|---|---|---|---|
| Mean | 1.09 ± 0.35 | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.05 ± 0.26 |
| CGI-BP - Depression(units on a scale) | Pre-Olanzapine | Pre-Placebo | New Olanzapine | Total |
|---|---|---|---|---|
| Mean | 2.23 ± 0.95 | 2.48 ± 0.82 | 3.55 ± 1.15 | 2.55 ± 1.08 |
1 further baseline measures are reported on the registry.
The record gives a start of Feb 2008, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine